# Summary of REMS for FDA-approved CAR T-cell products
| Product                             | CRS grade     | Tocilizumab   | Corticosteroids |
| :---                                |    :----:     |     :----:    |  :----:         |
| Abecma (idecabtagene vicleucel)     | Grade 1       | If onset 72 hours or more after infusion, treat symptomatically. If onset less than 72 hours after infusion, consider tocilizumab 8 mg/kg IV over 1 hour (not to exceed 800 mg).| Consider dexamethasone 10 mg IV
every 24 hours.|
